

5

10

**APPLICATION  
FOR  
UNITED STATES LETTERS PATENT**

15

**ON  
USE OF IMMUNOTOXINS TO INDUCE IMMUNE  
TOLERANCE TO PANCREATIC ISLET  
TRANSPLANTATION**

20

**BY**

**DAVID M. NEVILLE AND JUDITH M. THOMAS, citizens of the United States  
of America, residing at 9624 Parkwood Drive, Bethesda, Maryland 20814 and  
2117 Brook Highland Ridge, Birmingham, Alabama 35242, respectively.**

25

# USE OF IMMUNOTOXINS TO INDUCE IMMUNE TOLERANCE TO PANCREATIC ISLET TRANSPLANTATION

5

## BACKGROUND OF THE INVENTION

### Field of The Invention

This invention generally relates to techniques for inducing immune tolerance  
10 using an immunotoxin. In particular, this invention relates to the use of immune  
tolerance inducing techniques with pancreatic islet transplantation, for the purpose of  
inhibiting rejection of the transplant. This invention further relates to the treatment of  
diabetes using immune tolerance inducing techniques in conjunction with pancreatic islet  
transplantation.

15

### Background Art

There are 16 million diabetics within the United States. Ninety per cent of these  
have Type II diabetes, which is defined by hyperglycemia in the face of normal or  
elevated levels of circulating insulin. As Type II diabetes progresses, however, a  
20 decrease in circulating level of insulin may occur as the beta cells of the pancreatic islets  
produce and secrete less insulin. The mechanism of insulin resistance in Type II diabetes  
has not been elucidated, and the condition has proved to be difficult to treat and is  
currently the leading cause of renal failure in this country.

25 Type I diabetes results from pancreatic islet beta cell destruction and loss of  
insulin secretion secondary to an autoimmune process. Type I diabetes generally can be  
controlled by close monitoring of blood glucose concentration and multiple daily  
injections of exogenous insulin. Nonetheless, even with insulin replacement therapy,  
euglycemia is not achieved and at least one half of the Type I population cannot achieve  
30 sufficient control to prevent the complications of retinopathy, vasculopathy, and renal  
deterioration (71,72).

Allografts of pancreatic islets from cadaveric donors have been considered to offer a potential cure for Type I diabetes. Although reversal of type II diabetes by an islet xenograft transplant was described in one study in rodents (74), the conventional wisdom has been that this treatment would only work when insulin secretion was

5 subnormal. In fact clinical tests of islet transplantation have been limited largely to type I diabetics and patients who have previously undergone total pancreatectomy (75).

Even treatment of Type I diabetes with pancreatic islet allografts, however, has not been effective in freeing most patients from exogenous insulin injections (71,73).

10 The problem has been that the immunosuppressive reagents required to inhibit allograft rejection can severely compromise transplanted islet cell function (71). This is unlike the case of renal transplantation where cyclosporine A and corticosteroid derivatives do not severely compromise kidney function, in the majority of cases.

15 Transplant tolerance remains an elusive goal for patients and physicians whose ideal would be to see a successful, xenogeneic pancreatic islet transplant performed without the need for indefinite, non-specific maintenance immunosuppressive drugs and their attendant side effects. As with many transplant procedures, securing viable allogeneic grafts can be difficult. In addition, long term immunosuppression can be

20 problematic.

Over the past 10 years the majority of transplant recipients have been treated with cyclosporin, azathioprine, and prednisone with a variety of other immunosuppressive agents being used as well for either induction or maintenance

25 immunosuppression. The average annual cost of maintenance immunosuppressive therapy in the United States is approximately \$10,000. In addition to the cost, these agents, because of their non-specific effects, have considerable side effects, including compromising islet cell function and increasing susceptibility to infection. A major goal in pancreatic islet transplant immunobiology is the development of specific immunologic

30 tolerance to pancreatic transplants with the potential of freeing patients from the side

effects of continuous pharmacologic immunosuppression and its attendant complications and costs.

Anti-T cell therapy (anti-lymphocyte globulin) has been used in rodents in  
5 conjunction with thymic injection of donor cells (Posselt et al. *Science* 1990; 249: 1293-  
1295 and Remuzzi et al. *Lancet* 1991; 337: 750-752). Thymic tolerance has proved  
successful in rodent models and involves the exposure of the recipient thymus gland to  
donor alloantigen prior to an organ allograft from the same donor. However, thymic  
tolerance has never been reported in large animals, and its relevance to tolerance in  
10 humans is unknown.

One approach to try to achieve such immunosuppression has been to expose the  
recipient to cells from the donor prior to the transplant, with the hope of inducing  
tolerance to a later transplant. This approach has involved placement of donor cells  
15 (e.g. bone marrow) presenting MHC Class I antigens in the recipient's thymus shortly  
after application of anti-lymphocyte serum (ALS) or radiation. However, this approach  
has proved difficult to adapt to live primates (e.g. monkeys; humans). ALS and/or  
radiation render the host susceptible to disease or side-effects and/or are insufficiently  
effective.

20 If a reliable, safe approach to specific immunologic tolerance to pancreatic islet  
transplantation, particularly xenogeneic transplantation, could be induced, this would be  
of tremendous value and appeal to patients and transplant physicians throughout the  
world with immediate application to new transplants and with potential application to  
25 existing transplants in recipients with stable transplant function. Thus, a highly specific  
immune tolerance inducement is desired. Furthermore, there is a need for a means for  
imparting tolerance in primates, without the adverse effects of using ALS or radiation.  
Moreover, the goal is to achieve more than simply delaying the rejection response.  
Rather, an important goal is to inhibit the rejection response to the point that rejection is  
30 not a factor in reducing average life span among transplant recipients.

The present invention meets these needs by providing a method of inducing immune tolerance to pancreatic islet transplantation.

5

### SUMMARY OF THE INVENTION

The invention provides a method of treating diabetes in a subject, comprising administering to the diabetic subject an immunotoxin, thereby reducing the subject's T-cell population, and administering to the subject pancreatic islet cells from a donor. The method is effective for treating Type I or Type II diabetes. More specifically, the invention provides a short course immune tolerance inducing treatment regimen utilizing an anti-CD3 immunotoxin that, optionally with adjunct immunosuppressive agents, prevents pancreatic islet cell rejection while maintaining long term islet cell function following pancreatic islet cell transplantation. The invention further provides sufficient immune tolerance to pancreatic islet transplantation so that xenogeneic transplants are not rejected. Thus, the methods of the present invention provide a means for treating diabetes, wherein the need for exogenous insulin or immunosuppressive agents is eliminated.

A method of inducing immune tolerance using an immunotoxin for xenogeneic or allogeneic pancreatic islet cell transplantation is provided. Also provided is a method of inhibiting a rejection response of a transplant recipient, comprising administering an immunotoxin during the peritransplant period, thereby transiently reducing the number of T-cell lymphocytes and promoting long-term survival of the transplant.

25

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the rise in serum IFN-gamma following FN18-CRM9 immunotoxin treatment in post kidney transplant monkeys with and without treatment with DSG and solumedrol. The treatment dramatically attenuates the rise of IFN-gamma.

30

Figure 2a shows non-fasting blood glucose values of diabetic monkey 003B from pre-islet transplant to post transplant. Day 0 is the day of transplant. Top bar indicates the duration of immunosuppression. Bottom bar indicates the duration of exogenous insulin.

5

Figure 2b shows the glycosylated hemoglobin 1AC values on diabetic monkey 003B pre islet and post islet transplant. Normal and pathological ranges are for humans.

Figure 3a shows C-peptide values for diabetic monkey 003B pre islet and post islet transplant. Normal ranges (n) are for humans.

10

Figure 3b shows the results of an oral glucose tolerance test performed on monkey 003B 21 days post islet cell transplant. Normal ranges are for humans. Severe hyperglycemia before transplant precluded performing this test at that time.

15

Figure 4a shows C-peptide values for diabetic monkey X-550 pre islet and post islet transplant. Normal ranges (n) are for humans.

Figure 4b shows non-fasting blood glucose values on diabetic monkey X-550 from pre-islet transplant to post transplant. Day 0 is the day of transplant. Top bar indicates the duration of immunosuppression. Bottom bar indicates the duration of exogenous insulin.

20

## DETAILED DESCRIPTION OF THE INVENTION

25

The current invention provides a short course immune tolerance inducing treatment regimen utilizing an anti-CD3 immunotoxin that, optionally with adjunct immunosuppressive agents, prevents pancreatic islet cell rejection while maintaining long term islet cell function. A unique feature of the present immunotoxin immune tolerance induction is that the ratio of target cell toxicity (T cell) to non-target cell toxicity (islet cell) is extremely high. The adjunct immunosuppressive agents, which

30

can also be used and which can cause islet cell toxicity, such as cyclosporine and corticosteroid derivatives, are required only for a brief duration due to the power of the primary immunotoxin in promoting immune tolerance.

5           The invention provides a method of treating diabetes in a subject, comprising administering to the diabetic subject an immunotoxin, thereby reducing the subject's T-cell population, and administering to the subject pancreatic islet cells from a donor. Specifically, the method is effective for treating Type I or Type II diabetes. By "diabetes" is meant diabetes mellitus, a metabolic disease characterized by a deficiency  
10 or absence of insulin secretion or responsivity of peripheral tissues to insulin. As used throughout, "diabetes" includes Type I, Type II, Type III, and Type IV diabetes mellitus unless specified otherwise.

          Unexpectedly, the immune tolerance induction regimen of the invention  
15 successfully reverses type II diabetes in monkeys. The reversal of the insulin resistant state in non-human primates suffering from type II diabetes implies that the peripheral insulin resistance seen in this disease is, in some way, mediated by faulty islet function, and this condition can be largely reversed by healthy grafted islets. The present invention can reduce or eliminate the need for insulin replacement in the subject with  
20 Type I diabetes as well. In the case of both Type I and Type II, non-fasting blood glucose levels will preferably be maintained below 160 mg/dl upon completion of the immune tolerance induction regimen.

          By "pancreatic islet cells" is meant a composition comprising pancreatic islet  
25 cells. Preferably the pancreatic islet cells can be transplanted by injection of the cells into the portal vein; however, other cell, tissue, and organ transplantation paradigms well known in the art can be used. It is contemplated that the immunotherapeutic function of the present immunotolerance tolerance induction regimen can be applied to transplantation of all or part of the pancreas as well as to the transplantation of  
30 pancreatic islet cells.

The "donor" can be a cadaver or a living donor. Furthermore, the donor can be of the same species as the subject being treated or a different species than the subject being treated. Thus, using the method of the invention, transplantation can be performed across primate species (i.e., xenogeneic transplantation or xenograft) and within the same primate line (i.e., allogeneic transplantation or allograft). It was not obvious until this invention that the highly sensitive pancreatic islet xenografts would maintain function in the presence of this immune tolerance inducing regimen. Nor was it obvious that this regimen would permit an islet transplantation crossing species lines.

The invention further provides an immune tolerance inducing regimen, wherein a population of the pancreatic islet cells to be transplanted are modified to decrease antigenicity prior to transplantation. Specifically, the donor cells can be altered, such as by genetically engineering the donor or donor cells, to reduce pancreatic islet cell antigenicity or to reduce the susceptibility of pancreatic islet cells to immune injury (R. Weiss, Nature 391: 327-28 (1998)).

The "subject" being treated can include individual humans, domesticated animals, livestock (e.g., cattle, horses, pigs, etc.), and pets (e.g., cats and dogs).

The invention further provides a method, wherein the immunotoxin transiently reduces the subject's T cells in the blood and lymph nodes by at least one log unit. Preferably the number of T cells in the blood and lymph nodes will be transiently decreased by 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2 log units, or any interval amount between 0.7 and 2 log units.

By "transiently reduces" is meant that T cells are reduced by 0.7 to 2 log units in the blood and lymph compartments for at least four days before starting to return to normal levels.

The present method of inducing immune tolerance or treating diabetes further comprises administering an immunosuppressive agent to the subject. The



immunosuppressive agents can be administered beginning 24 to 0 hours prior to administration of the pancreatic islet cells to the recipient and continuing up to two weeks thereafter. Preferably, the immunosuppressive agents can be administered for at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days, or any interval time. The

5 immunosuppressive agent is selected from the group consisting of cyclosporine, mycophenolate mofetil, methyl prednisolone, deoxyspergualin, other known immunosuppressive agents, and any combination thereof. The immunotoxin regimen allows short-term immunosuppressive therapy and eliminates the need for long-term treatment with immunosuppressives, thereby avoiding the side effects associated with

10 chronic immunosuppression.

The immunotoxin is administered beginning at 24 to 0 hours before administration of the pancreatic islet cells and continuing up to several days thereafter. Preferably, the immunotoxin is administered for 1, 2, or 3 days or any time in between.

15 It is contemplated that immunotoxin administration of 4, 5, 6, or 7 days can be used if the production of antitoxin antibodies, which begins after approximately 5 days of administration, can be addressed. The immunotoxin can be administered in subjects beginning anytime after administration of the pancreatic islet cells. Thus, it is contemplated that a subject with a long term surviving transplant, who have not

20 previously received immunotoxin treatment, could still benefit from immunotoxin administration, thereby avoiding the need for long-term treatment with immunosuppressives. It is further contemplated that a transplant recipient who begins to show signs of rejection may benefit from immunotoxin administration to reduce or eliminate the rejection process.

25

The invention further provides a method of inhibiting a rejection response of a recipient of a pancreatic islet transplant by inducing immune tolerance in the recipient, comprising administering an immunotoxin during the peritransplant period, thereby transiently reducing the number of T-cell lymphocytes and promoting long-term survival

30 of the transplant. By "peritransplant period" is meant the period between 24 hours prior to and 2 weeks after transplantation.

Because of the close similarities between the immune functions that govern graft acceptance and rejection within primates and the similar functions of the pancreata within primates, this tolerance induction regimen is considered likely to succeed in humans for the treatment of diabetes via islet transplantation.

5

The immunotoxin can be a divalent anti-T cell immunotoxin, such as UCHT1-CRM9. More specifically, the divalent anti-T cell immunotoxin can be a single chain engineered fusion protein comprising an amino-terminus DT based toxin domain fused to a sFv domain (VL-linker-VH where linker is (Gly4Ser)<sub>3</sub> separated by a second linker and fused to a second identical sFv domain. The second linker can be (Gly4Ser)<sub>3</sub> or (Gly4Ser)<sub>5</sub>. Alternatively, the single chain engineered fusion protein can be monovalent providing that the linker and the VL and VH sequence are carefully chosen to provide an affinity lying within  $\pm 0.5$  log unit of the parental antibody affinity.

15

The divalent disulfide linked immunotoxin can have identical components. Alternatively, the components can be non-identical with only one toxin moiety to minimize steric hindrance of the antigen binding domains. The divalent anti-T cell immunotoxin can be a disulfide dimer of two monovalent single chain engineered fusion proteins that are dimerized via the hinge region of IgG1 or the  $\mu$ CH2 domain of IgM.

20 The dimer can be a homo dimer comprising two monovalent units of DT390-sFv-H- $\gamma$ CH3, disulfide dimerized by the single or double cysteine residues in H, the hinge region. The dimer alternatively can be a heterodimer comprising one monovalent unit of DT390-sFv-H- $\gamma$ CH3, disulfide dimerized by the single or double cysteine residues in H to a monovalent unit of sFv-H- $\gamma$ CH3. Dimerization can be achieved *in vivo* by

25 expression in a eukaryotic expression system modified for toxin resistance by an EF2 mutation. Examples are mutated CHO cells, Ss9 insect cells, or mutated yeasts. Alternatively, dimerization can be performed *in vitro* from monovalent species produced in prokaryote expression systems by the use of disulfide interchange reactions employing suitable disulfide oxidation systems such as dithiobisnitrobenzoic acid used to generate

30 mixed disulfide intermediates.

The divalent anti-T cell immunotoxin can comprise a toxin moiety and a targeting moiety directed to the T cell CD3 $\epsilon$  epitope. Even more specifically, the toxin moiety can be a diphtheria toxin binding site mutant. The immunotoxin can comprise a mutant toxin moiety (e.g., DT toxin or ETA toxin) linked to a single chain (sc) variable region antibody moiety (targeting moiety). Thus, the invention utilizes an immunotoxin having recombinantly produced antibody moiety linked (coupled) to a recombinantly produced toxin moiety and a fusion immunotoxin (where both toxin and antibody domains are produced from a recombinant construct). As the application provides the necessary information regarding the arrangement of toxin and antibody domains, and the sub regions within them, it will be recognized that any number or chemical coupling or recombinant DNA methods can be used to generate an immunotoxin. Thus, reference to a fusion toxin or a coupled toxin is not necessarily limiting.

The antibody moiety preferably routes by the anti-CD3 pathway. The immunotoxin can be monovalent, but divalent antibody moieties are presently preferred since they have been found to enhance cell killing by about 3 to 15 fold. The immunotoxin can be a fusion protein produced recombinantly. The immunotoxin can be made by chemical thioether linkage at unique sites of a recombinantly produced divalent antibody (targeting moiety) and a recombinantly produced mutant toxin moiety. The targeting moiety of the immunotoxin can comprise the human  $\mu$ CH2,  $\gamma$ CH3 and  $\mu$ CH4 regions and VL and VH regions from murine Ig antibodies. These regions can be from the antibody UCHT1 so that the antibody moiety is scUCHT1, which is a single chain CD3 $\epsilon$  antibody having human  $\mu$ CH2,  $\gamma$ CH3 and  $\mu$ CH4 regions and mouse variable regions. These are believed to be the first instances of sc anti-CD3 antibodies. Numerous DT mutant toxin moieties are described herein, for example DT390 or extensions of DT390 out to DT530. Thus, as just one specific example the immunotoxin, the invention provides scUCHT1-DT390. Derivatives of this immunotoxin are designed and constructed as described herein.

The engineered divalent immunotoxin utilized in the present invention can be stabilized with respect to divalency and disulfide bond initiation by the interactive Ig

domains of either human IgM  $\mu$ CH2 or IgG1  $\gamma$ CH3 or other similar Ig interactive domains.

In the present invention, the toxin moiety retains its toxic function and membrane  
 5 translocation function to the cytosol in full amounts. The loss in binding function  
 located in the receptor binding domain of the toxin protein diminishes systemic toxicity  
 by reducing binding to non-target cells. Thus, the immunotoxin can be safely  
 administered. The routing function normally supplied by the toxin binding function is  
 supplied by the targeting antibody, for example, anti-CD3. The essential routing  
 10 pathway is (1) localization to coated pits for endocytosis, (2) escape from lysosomal  
 routing, and (3) return to the plasma membrane.

The mutant DT toxin moiety can be a truncated mutant, such as DT390,  
 extensions of DT390 out to DT530, or other truncated mutants, as well as a full length  
 15 toxin with point mutations or CRM9 (cloned in *C. ulcerans*), scUCHT1 fusion proteins  
 with DTM1 and DT483. DT390 has been cloned and expressed in *E. coli*. The toxin  
 domain can be CRM9 (DT535, S525F) plus a second attenuating mutation from the  
 group: F530A, K516E, K516A, Y514A, V523A, N524A). The antibody moiety can be  
 scUCHT1 or other anti-CD3 antibody having the routing and other characteristics  
 20 described in detail herein. Thus, one example of an immunotoxin for use in the present  
 methods is the fusion protein immunotoxin DT390sSvUCHT1. In principal, described  
 immunotoxins can be used in the methods of the invention.

The immunotoxin or components thereof can be expressed in *E. coli* BL21DE3  
 25 cytosol using TrxB<sup>-</sup> strains at 15 to 25°C. Alternatively, the immunotoxin or components  
 thereof can be expressed in eukaryotic cell lines (such as CHO), insect cell lines (such  
 as Ss9), and yeast cell lines (such as *Pichia pastoris*) provided that the toxin  
 glycosylation sites at residues 16 and 235 are eliminated and the cells have been mutated  
 to resist ADP-ribosylation catalyzed by toxin, by a Gly to Arg substitution 2 residues to  
 30 the carboxyl side of the modified amino acid diphthamide. In the case of insect cells this

mutant EF-2 can be supplied in the same baculovirus vector supplying the immunotoxin gene since two late promoters are available in baculovirus.

The recombinant immunotoxins can be produced from recombinant sc divalent  
 5 antibody or recombinant dicystronic divalent antibody and recombinant mutant toxins  
 each containing a single unpaired cysteine residue. An advantage of this method is that  
 the toxins are easily produced and properly folded by their native bacteria while the  
 antibodies are better produced and folded in eukaryote cells. In addition, this addresses  
 differences in coding preferences between eukaryotes and prokaryotes which can be  
 10 troublesome with some immunotoxin fusion proteins.

The general principles for producing the present divalent recombinant anti-T cell  
 immunotoxins are:

- 15           1.       The disulfide bond bridging the two monovalent chains is chosen from a  
 natural Ig domain, for example from  $\mu$ CH2 (C337 of residues 228-340 or the  $\gamma$ IgG  
 hinge region, C226 or C229 or both of residues 216-238 [with C220P]).
- 20           2.       Sufficient non-covalent interaction between the monovalent chains is  
 supplied by including domains having high affinity interactions and close crystallographic  
 or solution contacts, such as  $\mu$ CH2,  $\mu$ CH4 (residues 447-576) or  $\gamma$ CH3 (residues  
 376-446). These non-covalent interactions facilitate proper folding for formation of the  
 interchain disulfide bond.
- 25           3.       For fusion immunotoxins the orientation of the antibody to the toxin is  
 chosen so that the catalytic domain of the toxin moiety becomes a free entity when it  
 undergoes proteolysis at its natural processing site under reducing conditions. Thus, in  
 the ETA based IT, the toxin moiety is at the carboxy terminus and, in DT based fusion  
 IT, the DT based toxin moiety is at the amino terminus of the fusion protein.

4. For chemically coupled immunotoxins, a single cysteine is inserted within the toxin binding domain. The antibody is engineered to have only a single free cysteine per chain which projects into the solvent away from interchain contacts such as  $\mu$ CH3 414,  $\mu$ CH4 575 or the addition to  $\gamma$ CH3 at C447. Crystal structure indicates this region is highly solvent accessible. Excess free cysteines are converted to alanine. Alternatively, a C terminal cysteine can be added to  $\gamma$ CH3 directly following a histidine tag for purification,  $\gamma$ CH3 (His)6Cys.

5. Toxins are mutated in their binding domain by point mutations, insertions or deletions, have at least a 1000 fold reduction in binding activity over wild type, and are free of translocation defects.

6. Toxin binding site mutants, if not capable of proteolytic processing at neutral pH, are modified in the processing region to achieve this result.

15 A binding site mutant (CRM9) of full length diphtheria toxin residues 1-535 using the numbering system described by Kaczovek et al. (56) S525F (57) can be further modified for chemical coupling by changing a residue in the binding domain (residues 379-535) to cysteine. Presently preferred residues are those with exposed solvent areas greater than 38%. These residues are K516, V518, D519, H520, T521, V523, K526, F530, E532, K534 and S535 (57). Of these K516 and F530 are presently preferred since they are likely to block any residual binding activity (57). However, maximal coupling of the new cysteine residue will be enhanced by the highest exposed solvent surface and proximity to a positively charged residue (which has the effect of lowering cysteine -SH pKa). These residues are at D519 and S535 so that these are presently preferred from the above list of possibilities.

A double mutant of DT containing the S525F mutation of CRM9 plus an additional replacement within the 514-525 exposed binding site loop to introduce a cysteine coupling site for example T521C can be produced in *Corynebacterium ulcerans* preceded by the CRM9 promoter and signal sequence. The double mutant is made in

Corynebacterium ulcerans by a recombination event between the plasmid producing CRM9-antibody fusion protein and PCR generated mutant DNA with a stop codon at 526 (gapped plasmid mutagenesis). Alternatively, double attenuating mutants of diphtheria toxin can be produced in *E. coli* BL21DE3 TrxB<sup>-</sup> by PCR mutagenesis without the use of a signal sequence. These CRM9-Cs can be used to form specific thioether mutant toxin divalent antibody constructs by adding excess bismaleimido-hexane to CRM9-Cs and coupling to single chain divalent antibody containing a free cysteine at either the end of the  $\mu$ CH4 domain or the  $\gamma$ CH3 domain (see Serial No. 08/739,703, hereby incorporated by reference).

These and other mutations are accomplished by gapped plasmid PCR mutagenesis (58) using the newly designed *E. coli*/C. ulcerans shuttle vector yCE96 containing either the double mutant DT S508F S525F or a CRM9 COOH terminus fusion protein construct having reduced toxicity due to the COOH terminal added protein domain (59).

The mutated toxins are produced and purified analogously to the parent toxin except that low levels of reducing agent (equivalent to 2 mM betamercaptoethanol) are included in the purification to protect the unpaired introduced -SH group. Thioether chemical coupling is achieved to a single unpaired cysteine within the divalent antibody construct at either residue 414 in domain  $\gamma$ CH3 or residue 575 in domain  $\mu$ CH4 when this domain is included. In this case domain  $\gamma$ CH3 is mutated C414A to provide only a single coupling site. An advantage of including  $\mu$ CH4 is enhanced stability of the divalent antibody. A disadvantage is that the extra domain increases size and thereby reduces the secretion efficiency during antibody production. The advantage of terminating with the  $\gamma$ CH3 domain is that, in another variant, a His6 purification tag can be added at either the  $\mu$ CH2 COOH or  $\gamma$ CH3 COOH terminus to facilitate antibody purification. Another variant is to use the  $\gamma$  hinge region to form the interchain disulfide and to couple through a  $\gamma$ CH3 or  $\mu$ CH4. This variant has the advantage of being smaller in size and places the toxin moiety closer to the CD3 epitope binding domains, which could increase toxin membrane translocation efficiency. A His tag can be

included at the carboxy terminus as a purification aid. SH-CRM9 is concentrated to 10 mg/ml in PBS pH 8.5 and reacted with a 15 fold molar excess of bismaleimidohexane (BMH) (Pierce, Rockford, IL). Excess BMH is removed by passing over a small G25F column (Pharmacia, Piscataway, NJ). The maleimide derived toxin at about 5 mg/ml is now added to scUCHT1 divalent antibody at 10 mg/ml at room temperature. After 1 hr the conjugate is separated from non-reactive starting products by size exclusion HPLC on a 2 inch by 10 inch MODcol column packed with Zorbax (DuPont) GF250 6 micron resin (for large scale production). Derivatives of ETA60EF61cys161 are also coupled to scUCHT1 divalent antibody by the same method.

10

Divalent anti-T cell fusion immunotoxins based on DT can be utilized in the invention, wherein the toxin domain (also referred to herein as "toxin moiety" or "tox") is either full length mutant S525F (CRM9) or truncated at 390 or 486 (collectively Tox) and the sequence of domains from the amino terminus from left to right can be selected from among the following and may include C terminal or amino terminal His purification tags: VL and VH are the variable light and heavy domains of the anti-CD3 antibody UCHT1 or other anti-CD3 antibody. H is the human IgG1 hinge.

20

Single chain divalent fusion protein: Tox, VL, L, VH, L, VL, L, VH;

Single chain univalent fusion protein homodimerized via  $\mu$ CH2 337 Cys:  
(Tox, VL, L, VH,  $\mu$ CH2)<sub>2</sub>;

25

Single chain univalent fusion protein homodimerized via H 226/229 Cys:  
(Tox, VL, L, VH, H,  $\gamma$ CH3)<sub>2</sub>;

Single chain univalent fusion protein heterodimerized via  $\mu$ CH2 337 Cys:  
(Tox, VL, L, VH,  $\mu$ CH2  
VL, L, VH,  $\mu$ CH2);

30



Single chain univalent fusion protein heterodimerized via H 226/229 Cys:  
 (Tox, VL, L, VH, H,  $\gamma$ CH3  
 VL, L, VH, H,  $\gamma$ CH3);

- 5 sFv-SH fusion protein homodimerized via H 226/229 Cys chemically linked via a bis maleimide (R) to a SH derivatized CRM9 or a CRM9 containing an engineered C terminal cysteine (Tox): VL, L, VH, H,  $\gamma$ CH3, His6, Cys-S-R-S-Tox.
- 10 Other types of protein toxin moieties can be utilized in anti-T cell immunotoxins for the induction of tolerance. All that is required is that a 1-2 log kill of T cells within the blood and lymph node compartments can be achieved without undue systemic toxicity. This in turn requires that the routing epitope routes in parallel with the toxin intoxication pathway and that binding site mutants are available or that toxins truncated
- 15 in their binding domain are available that reduce toxin binding by 1000 fold compared to wild type toxins without compromising toxin translocation efficiency (see U.S. Patent No. 5,167,956 issued December 1, 1992). In addition when using targeting via antibodies, divalent antibodies are generally required under *in vivo* conditions to achieve sufficient cell killing due to the 3 to 15 fold lower affinity of monovalent antibodies.
- 20 However, the method of linking the toxin to the divalent antibody either as a single chain fusion protein or through specific engineered coupling sites must not interfere with translocation efficiency. This could occur due to the larger size of many divalent antibodies compared to monovalent scFv antibodies unless care is taken so that the catalytic domain of the toxin can achieve unencumbered translocation. This is achieved
- 25 for DT based immunotoxins using DT based binding site mutants where the fusion protein antibody moiety is contiguous with the COOH terminus of the toxin binding chain as described above. This allows the catalytic a chain to translocate as soon as the disulfide loop spanning the Arg/Ser proteolytic processing site residues 193/194 is reduced. Most targeted cells are capable of performing this processing event, and when
- 30 chemically coupled CRM9 is used the processing is performed by trypsin prior to coupling.

If the toxin moiety is based on full length diphtheria toxin, it can include the following mutations:

S525F, K530C

S525F, K516C

5 S525F, D519C

S525F, S535C.

The antibody-toxin constructs utilized in the invention can be expected to be effective as immunotoxins because the relevant parameters are known. The following discussion of parameters is relevant to the use of the immunotoxin in tolerance induction. The relevant binding constants, number of receptors and translocation rates for humans have been determined and used. Binding values for anti-CD3-CRM9 for targeted and non-targeted cells *in vitro* and rates of translocation for the anti-CD3-CRM9 conjugate to targeted and non-targeted cells *in vitro* are described (Greenfield et al. (1987) *Science* 238:536; Johnson et al. (1988) *J. Biol. Chem.* 263:1295; Johnson et al. (1989) *J. Neurosurg.* 70:240; and Neville et al. (1989) *J. Biol. Chem.* 264:14653). The rate limiting translocation rate to targeted cells *in vitro* is shown as follows: an anti-CD3-CRM9 conjugate at  $10^{-11}$  M is translocated to about 75% of the target cells present as measured by inhibition of protein synthesis in about 75% of cells with 20 hours. Inhibition of protein synthesis is complete in cells into which the conjugate translocates.

Parameters determined in *in vivo* studies in nude mice include the following: Tumor burden is described in Example 1 as a constant mass equal to 0.1% of body weight; the receptor number and variation of receptor number are described in Example 3; "favorable therapeutic margin" is defined as an *in vivo* target cell 3 log kill at 0.5 MLD (minimum lethal dose) comparison of efficacy with an established treatment of 0.5 MLD immunotoxin equivalent (group 1) to a radiation dose of 500-600 cGy (groups 8 and 9).

The parameters determined *in vitro* allowed the prediction of success in the *in vivo* nude mouse study. The prediction of *in vivo* success was verified by the data in Examples 3-4. Using the target cell number from the mouse study as being equivalent to the local T cell burden in a monkey or man successful T cell ablation and  
5 immunosuppression in monkeys could be predicted. This prediction has been verified by the monkey data in Example 5. Using the same parameters, a scientist skilled in this field can make a prediction of success in humans with confidence, because these parameters have been previously shown to have predictive success.

10 Most human sera contain anti-DT neutralizing antibodies from childhood immunization. To compensate for this the therapeutic dose of anti-CD3-CRM9 can be appropriately raised without affecting the therapeutic margin. Alternatively, a non-toxic DT mutants reactive with neutralizing antisera (e.g., CRM197) that can be administered in conjunction with the immunotoxin. See U.S. Patent No. 5,725,857, the content of  
15 which is incorporated herein by reference.

One embodiment to the invention provides a method of inhibiting a rejection response by inducing immune tolerance in a recipient to a foreign donor pancreatic islet cell by exposing the recipient to an immunotoxin so as to reduce the recipients's  
20 peripheral blood T-cell lymphocyte population by at least 80%, and preferably 95% or higher, wherein the immunotoxin is an anti-CD3 antibody linked to a diphtheria protein toxin, and wherein the protein has a binding site mutation. The term "donor cell" refers to a donor pancreatic islet cell or cells, as distinguished from donor lymphocytes or donor bone marrow. When the donor pancreatic islet cells are transplanted into the  
25 recipient, a rejection response by the recipient to the donor cells is inhibited and the recipient is tolerized to the donor organ or cell. Alternatively, a non-toxic DT mutant such as DTM2 or CRM197 can first be administered followed by the immunotoxin. This method can use any of the immunotoxins (e.g., anti-CD3-CRM9, scUCHT1-DT390, etc.) or non-toxic DT mutants described herein with the dosages and modes of  
30 administration as described herein or otherwise determined by the practitioner.

The present tolerance induction method can also include administering an immunosuppressant compound before, at the same time, or after the immunotoxin exposure step. The immunosuppressant compound can be cyclosporine (*e.g.*, *cyclosporine A*) or other cyclophylins, mycophenolate mofetil (Roche), methyl  
 5 prednisone, deoxyspergualin (Bristol Myers), FK506, other known immunosuppressants, or any combination thereof. It will be appreciated that certain of these immunosuppressants have major effects on cytokine release occurring in the peritransplant period that may aid in the induction of the tolerant state. The method of inducing immune tolerance can further comprise administering donor bone marrow at  
 10 the same time or after the exposure step.

Any one, two, or more of these adjunct therapies can be used together in the present tolerance induction method. Thus, the invention includes at least six methods of inducing tolerance using immunotoxin (IT): (1) tolerance induction by administering IT  
 15 alone; (2) tolerance induction by administering IT plus other drugs that alter immune function such as high dose corticosteroids; (3) tolerance induction by administering IT plus immunosuppressant drugs, such as mycophenolate mofetil and/or deoxyspergualin; (4) tolerance induction by administering IT plus other drugs that alter immune function, plus immunosuppressant drugs; (5) tolerance induction by administering IT and bone  
 20 marrow; and (6) tolerance induction by administering IT plus bone marrow, plus immunosuppressant drugs. The adjunct therapy can be administered before, at the same time or after the administration of immunotoxin. Different adjunct therapies can be administered to the recipient at different times or at the same time in relation to the transplant event or the administration of immunotoxin, as further described below.

25

Because the immunosuppressant can be administered before the immunotoxin and/or other treatments, the present method can be used with a patient that has undergone an organ transplant and is on an immunosuppressant regimen. This presents a significant opportunity to reduce or eliminate traditional immunosuppressant therapy  
 30 and its well documented negative side-effects. Also, as described below, treatment with immunosuppressants prior to transplantation could be particularly useful in cadaveric

and xenogeneic transplants. In such a setting of pre-transplant treatment with immunosuppressant, the administration of immunotoxin can be delayed for up to seven or more days post-transplantation.

- 5           An example of a schedule of immunotoxin and immunosuppressant administration for patients receiving organ transplants is as follows:

- |    |                      |   |
|----|----------------------|---|
|    | day -24 to -0 hours: | begin immunosuppressant treatment;                                  |
|    | day 0                | : perform transplant;   |
| 10 | day 0                | : immediately following transplant administer 1st immunotoxin dose; |
|    | day 1                | : 2nd immunotoxin dose;   |
|    | day 2                | : 3rd and final immunotoxin dose.                                   |

- 15   Immunosuppressant treatment may end at day 3 or extend to day 14. Immunosuppressant treatment is also effective if begun at the time of transplantation, and can continue for up to two weeks after transplantation.

- 20           The presently preferred doses of the immunotoxin are those sufficient to deplete peripheral blood T-cell levels to 80%, preferably 90% (or especially preferably 95% or higher) of preinjection levels. This should require mg/kg levels for humans similar to those for monkeys (e.g., 0.05 mg/kg to 0.3 mg/kg body weight), which toxicity studies indicate should be well tolerated by humans. Thus, the immunotoxin can be administered to safely reduce the recipients T cell population.

25

### EXAMPLE 1

#### Establishment of Tumors

- 30           The experimental design of the studies that give rise to the present invention was dictated by the goal of having an animal model as closely relevant to human *in vivo*

tumor therapy as possible. In order to minimize the host killer cell immune response, bg/nu/xid strain of nude mice were used (Kamel-Reid and Dick (1988) *Science* 242:1706). The human T cell leukemia cell line, Jurkat, was chosen because of previous studies with this line and its relatively normal average complement of CD3 receptors (Preijers et al. (1988) *Scand. J. Immunol.* 27:553). The line was not cloned so that receptor variation among individual cells existed. a scheme was developed whereby well established tumors of constant mass equal to 0.1% of body weight ( $\approx 4 \times 10^7$  cells) could be achieved 7 days after inoculation of Jurkat cells (see Dillman et al. (1988) *Cancer Res.* 15:5632). This required prior irradiation and inoculation with lethally irradiated helper feeder cells (see Dillman et al. (1988) *Cancer Res.* 15:5632).

Nude mice bg/nu/xid maintained in a semi-sterile environment are preconditioned with 400 cGy whole body  $^{137}\text{CS}$   $\gamma$  radiation on day -7. On day 0,  $2.5 \times 10^7$  Jurkat cells (human T cell leukemia CD3+, CD4+, CD5+) are injected subcutaneously with  $1 \times 10^7$  HT-1080 feeder cells (human sarcoma) which have received 6000 cGy. Jurkat cells were passaged every other week in mice as subcutaneous tumors and dissociated by collagenase/dispase prior to inoculation. This cell population exhibits a 40% inhibition of protein synthesis after 5 hours exposure to  $10^{11}$  M anti-CD3-DT. Clones isolated from this population by infinite dilution exhibit varying sensitivity to anti-CD3DT (4 less sensitive, 3 more sensitive) corresponding to a 1.5 log variation in dose response curves. Immunotoxin treatment is given by intraperitoneal injection starting on day 7 when the tumor is visibly established. Evaluation takes place on day 37.

## EXAMPLE 2

### Guinea Pig Studies

Immunotoxin toxicity studies were performed in guinea pigs, an animal (like humans) with a high sensitivity to diphtheria toxin (mice are highly resistant to diphtheria toxin). Therapy of CRM9 conjugates was set at  $\frac{1}{2}$  the guinea pig minimum

lethal dose. In this study, minimum lethal dose (MLD) is defined as the minimum tested dose which results in both non-survivors and survivors over a 4 week evaluation period. All animals survive when a MLD is reduced by 0.5. MLD was evaluated in guinea pigs (300-1000 g) by subcutaneous injection. The following MLDs were found and are listed as  $\mu\text{g}$  of toxin/kg body weight; DT, 0.15; CRM9, 30; anti-CD5-DT (cleavable), 0.65; anti-CD5-CRM9 (non-cleavable), 150. Finally, the therapeutic efficacy of the immunotoxin treatment in producing tumor regressions was compared to graded doses of whole body irradiation which resulted in similar tumor regressions.

### EXAMPLE 3

#### Comparison of Immunotoxins

Several types of immunotoxins were compared in this study. They were synthesized as previously described by thiolating both the monoclonal antibody moiety and the toxin moiety and then crosslinking the bismaleimide crosslinkers (Neville et al. (1989) *J. Biol. Chem.* 264:14653). Purification was performed by size exclusion HPLC columns and fractions containing 1:1 toxin:antibody mol ratios were isolated for these studies. Conjugates made with an acid-labile crosslinker bismaleimidoethoxy propane were compared with a non-cleavable, bismaleimidohexane. Conjugates made with this cleavable crosslinker have been shown to hydrolyze within the acidifying endosome releasing free toxin moieties with half-times of hydrolysis measured at pH 5.5 of 36 min (Neville et al. (1989) *J. Biol. Chem.* 264:14653).

The results of this study are tabulated in Table I. Non-treatment groups such as group 10, groups treated with anti-CD5 immunotoxins (groups 5 and 6), and group 4 treated with a mixture of anti-CD3 and CRM9 did not show regression. The vascularized tumor nodules that weighed 20 mg on day 7 grew to between 1.5 to 7.8 g on day 37 and weighed between 7.9 and 11.6 on day 56. No late spontaneous regressions were noted. In contrast, group 1 consisting of treatment with anti-CD3-

CRM9 non-cleavable conjugate (NC) given at 25  $\mu\text{g/kg}$  on days 7, 8, and 9 showed only 1 tumor out of 6 by day 37. Some of the remaining animals were subject to autopsy and they failed to reveal residual tumor or even scarring. Tumors identified as regressed on day 37 by superficial inspection did not reappear during the course of the study (56  
5 days).



**TABLE 1. IMMUNOTOXIN AND RADIATION TREATMENT ON SUBCUTANEOUS HUMAN T CELL TUMORS (JURKAT) IN NUDE MICE**

Group	Treatment	Dose (intraperitoneal)	Animals Bearing Tumors At Day 37/Group Animals	% Tumor Regressions
1	Anti-CD3-CRM9 (NC) <sup>a</sup>	25 $\mu$ g/kg. x 3d	1/6	83
2	Anti-CD3-CRM9 (NC) Anti-CD5-CRM9 (C)	19 $\mu$ g/kg. x 2d 19 $\mu$ g/kg. x 2d	1/4	75
3	Anti-CD3-CRM9 (C)	25 $\mu$ g/kg. x 3d	2/4	50
4	Anti-CD3+CRM9	25 $\mu$ g/kg. x 3d	4/4	0
5	Anti-CD5-CRM9 (C)	25 $\mu$ g/kg. x 3d	5/5	0
6	Anti-CD5-DT (NC)	25 $\mu$ g/kg. x 1d	9/9	0
7	$\gamma$ radiation <sup>137</sup> Cs	400 cGy	2/2	0
8	$\gamma$ radiation <sup>137</sup> Cs	500 cGy	3/6	50
9	$\gamma$ radiation <sup>137</sup> Cs	600 cGy	0/2 <sup>b</sup>	100
10	None		6/6	0

<sup>a</sup>Anti-CD3 refers to the monoclonal antibody UCHT1 and was purchased from Oxoid USA, Inc. Anti-CD5 refers to the monoclonal antibody T101 and was a gift from Hybritech (San Diego). NC and C refer, respectively, to non-cleavable and cleavable conjugates.

<sup>b</sup>These animals were evaluated on days 10 and 13 at the time of death from radiation sickness.

The cleavable crosslinker confers no therapeutic advantage to anti-CD3-CRM9 immunotoxins and may be less effective (group 3). Cleavable crosslinkers confer some advantage with anti-CD5-CRM9 conjugate *in vitro* (5) but had no effect in this *in vivo* system (group 5), and lacked significant potentiating effect when administered with anti-CD3-CRM9 (group 2). The cleavable crosslinker conferred a marked therapeutic advantage to anti-CD5 wild type toxin conjugates and tumor regressions were achieved. However, in these cases the guinea pig toxic dose was exceeded. a single dose on day 7 of cleavable anti-CD5-DT at 6  $\mu\text{g/kg}$  produced 8/10 tumor regressions while a cleavable conjugate made with an irrelevant antibody (OX8) produced no regressions (4/4). However, this dose exceeded the guinea pig MLD by 9 fold. a rescue strategy was tried in which the above conjugate dose was given intravenously followed by DT antitoxin 4 hours later (also intravenously). The 4 hr rescue could not raise the MLD above 0.65  $\mu\text{g/kg}$ . The 1 hr rescue could not raise the MLD above 0.65  $\mu\text{g/kg}$ . The 1 hr rescue raised the MLD to 36  $\mu\text{g/kg}$ , however, there were no tumor regressions in 10 mice receiving 21.5  $\mu\text{g/kg}$  of the cleavable anti-CD5-DT conjugate.

In groups 7-9 increasing single doses of whole body radiation (102 cGy/min) were given to animals bearing 3x3x5 mm tumors. At 400 cGy no complete regressions occurred. At 500 cGy 50% complete tumor regressions occurred. At 600 cGy 100% regression was achieved as judged on day 10 and 13 when the animals died from radiation sickness. (Groups 7-9 did not receive prior radiation and tumor takes were less than 100%). It appears that the 75  $\mu\text{g/kg}$  anti-CD3-CRM9 (NC) immunotoxin is equal in therapeutic power to between 500 and 600 cGy of radiation.

25

#### EXAMPLE 4

##### Estimation of Cell Kill

The actual cell kill achieved by the radiation and the immunotoxin can be estimated by assuming radiation single hit inactivation kinetics along with a  $D_{37}$  value for

30

the radiation. a value for  $D_{37}$  of 70-80 cGy with  $n = 1.2-3$  is not unreasonable for a rapidly dividing helper T cell.  $D_{37}$  is the dose of radiation which reduces the fraction of surviving cells to  $1/e$  as extrapolated from the linear portion of the log survivors vs. dose curve and  $n$  is the intercept at 0 dose (Anderson and Warner (1976) in *Adv. Immunol.*, Academic Press Inc., 24:257). At a dose of 550 cGy the fraction of surviving cells is calculated to be about  $10^3$ . Since a majority of tumors completely regress at this dose we estimate that both therapies are producing an approximate 3 log kill. (The remaining cells,  $4 \times 10^7 \times 10^3 = 4 \times 10^4$  cells apparently cannot maintain the tumor, i.e., the *in vivo* plating efficiency is low, a fairly typical situation in the nude mouse xenograft system.)

The reliability of this 3 log kill estimate has been verified by determining the tissue culture plating efficiency by limiting dilution of 7 day established Jurkat tumors (following dispersal) and tumors exposed 18 hours earlier *in vivo* to 600 cGy. Plating efficiencies were 0.14 and  $1.4 \times 10^4$ , respectively. (Plating efficiency is the reciprocal of the minimum average number of cells per well which will grow to form one colony.

It should be emphasized that with high affinity holo-immunotoxins the cell kill is inversely proportional to the target cell number. This presumably occurs because receptors are undersaturated at tolerated doses and free conjugate concentration falls with increasing target cell burden (Marsh and Neville (1987) *Ann. N.Y. Acad. Sci.* 507:165; Yan et al. (1991) *Bioconjugate Chem.* 2:207). To put this in perspective, the tumor burden in this study is almost equal to the number of T cells in a mouse ( $\approx 10^8$ ). It can be expected that a tolerated dose of anti-CD3-CRM9 immunotoxin can achieve an *in vivo* 3 log depletion of a normal number of CD3 positive T cells.

**EXAMPLE 5****T-Cell Depletion in Rhesus Monkeys  
Induced by FN18-CRM9**

5

**FN18-CRM9 conjugate**

The monoclonal antibody FN18 is the monkey equivalent of the human anti-CD3 (UCHT1) and is known to bind the same CD3 receptor epitopes ( $\epsilon$  and  $\gamma$ ) as bound by the human CD3 antibody and is the same isotype as the human CD3 antibody. Thus, in terms of the parameters relevant for predicting successful T cell depletion, the present CD3-CRM9 conjugate and FN18-CRM9 are expected to have the same activity.

**Administration**

Conjugates can be administered as an I.V. bolus in a carrier consisting of 0.1 M  $\text{Na}_2\text{SO}_4$  + 0.01 M phosphate buffer, pH 7.4. The dose schedule is every other or third day for about 3 days. The total dose is preferably from 50 to 300 micrograms of toxin per kg of body weight.

The actual dose of FN18-CRM9 used was varied between 0.167 - 1.13 of the minimum lethal dose (MLD) in guinea pigs. Since the estimation of the MLD was performed in an animal lacking an immunotoxin target cell population (guinea pigs), the true MLD of FN18-CRM9 and anti-CD3-CRM9 is expected to be higher in monkeys and humans than in guinea pigs.

**25 T Cell Kill**

Helper T cell ( $\text{CD4}^+$  cells) numbers in peripheral blood fell dramatically after the initial administration of FN18-CRM9 in two rhesus monkeys. T cell counts began to rise by day 4 (sampled just prior to the second dose of FN18-CRM9). On day 5 in monkey 8629,  $\text{CD4}^+$  cells were depressed below the limit of detection ( $<50 \text{ cells/mm}^3$ ). Cells remained below or equal to  $200/\text{mm}^3$  out to day 21. This low level of  $\text{CD4}^+$  cells is associated with profound immunodeficiency in humans and in monkeys (Nooij and

Jonker (1987) *Eur. J. Immunol.* 17:1089-1093). The remarkable feature of this study is the long duration of helper T cell depletion (day 21) with respect to the last administration of immunotoxin (day 4) since intravenously administered immunotoxins were cleared from the vascular system with half-lives <9 hours (Rostain-Capaillon and Casellas (1990) *Cancer Research* 50:2909-2916), the effect outlasting circulating immunotoxin. This is in contrast to T cell depletion induced by unconjugated anti-CD3 antibodies (Nooij and Jonker (1987) *Eur. J. Immunol.* 17:1089-1093).

In monkey 1WS the second dose of conjugate only appeared to result in a diminished rate of CD4+ cell recovery. However, CD4+ cells were still fewer than normal at day 21. The blunted response of monkey 1WS to the second dose of immunotoxin was found to be due to a preexisting immunization of this animal to the toxin. Monkey 1WS had a significant pre-treatment anti-diphtheria toxin titer as revealed by a Western blot assay. This titer was markedly increased at day 5, indicative of a classic secondary response. In contrast, monkey 8629 had no detectable pre-treatment titer and only a trace titer by day 5 and a moderate titer by day 28.

The specificity of FN18-CRM9 toward T cells can be seen by comparing the total white blood cell (WBC) count in the same two monkeys. WBCs fell, but only to 45% of baseline value on day 2 compared to 6% of baseline values for the CD4+ T cell subset. Most of the fall in WBC values can be accounted for by the T cell component of the WBC population ( $\approx 40\%$ ). However, B cells are initially depleted after FN18-CRM9 although these cells recover more quickly. FN18 is an IgG<sub>1</sub> isotype and as such is known to bind to Fc $\gamma$  receptors present on B cells and macrophages with low affinity. The FN18-CRM9 depletion of B cells indicates that significant interactions between the Fc portion of the FN18 antibody and B cells is taking place.

The peripheral T cell depletion induced by unconjugated FN18 at a dose known to produce immunosuppression 0.2 mg/kg/day (Nooij and Jonker (1987) *Eur. J. Immunol.* 17:1089-1093) was compared to the immunotoxin FN18-CRM9 administered at 1/9th the FN18 dose. Peripheral CD4+ T cell depletion is more pronounced and

more long-lasting with the conjugate. The demonstration that FN18-CRM9 reduces peripheral helper T cell subset (CD4+) to levels less than or equal to 200 cell/mm<sup>3</sup> for a period as long as 21 days demonstrates that this immunotoxin and its anti-human analogs are effective immunosuppressive reagents.

5

The demonstration that FN18-CRM9 is a potent agent for inducing T cell depletion in non-human primates demonstrates that an anti-human homolog of FN18-CRM9, UCHT1-CRM9 (Oxoid USA, Charlotte, NC) for example, is a potent agent for inducing T cell depletion in humans.

10

The Fc binding region of anti-TCR/CD3 monoclonals may or may not be needed to induce T cell depletion when the anti-TCR/CD3 monoclonals are conjugated to CRM9. The Fc<sub>II</sub> binding regions can be removed, for example, by forming the conjugates with F(ab')<sub>2</sub> derivatives as is indicated in the literature (Thorpe et al. (1985) *J. Natl. Cancer Inst.* 75:151-159). In addition, anti-TCR/CD3 IgA switch variants such as monoclonal antibody T3. a may be used (Ponticelli et al. (1990) *Transplantation* 50:889-892). These avoid rapid vascular clearance characteristic of F(ab')<sub>2</sub> immunotoxins. F(ab')<sub>2</sub> and IgA switch variants of anti-TCR/CD3-CRM9 immunotoxins are therefore derivative anti-TCR/CD3 immunotoxins. These derivatives will avoid the B cell interaction noted and can increase specificity. However, IgG<sub>2a</sub> switch variants will maximize T cell activation through the Fc<sub>γ</sub> receptor and may be useful in certain situations where T cell activation aids immunotoxin induced toxicity.

General methods to make antibodies lacking the Fc region or to make antibodies which are humanized are set forth in Harlow and Lane, *Antibodies: a Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988. Thus, as used in the claims, antibody can mean the entire antibody or any portion of the antibody sufficient for specific antigen or receptor binding.

25

**EXAMPLE 6**

**An anti-CD3 single-chain immunotoxin with a  
truncated diphtheria toxin decreases inhibition by  
pre-existing antibodies in human blood**

5 The present Example examines the effect of human serum with pre-existing  
anti-DT antibodies on the toxicity of UCHT1-CRM9, an immunotoxin directed against  
CD3 molecules on T-lymphocytes. Sera with detectable anti-DT antibodies at 1:100 or  
10 greater dilutions inhibited the immunotoxin toxicity. Experiments with  
radiolabeled-UCHT1-CRM9 indicate that anti-DT antibodies partially block its binding  
to the cell surface as well as inhibit the translocation from the endosome to the cytosol.  
The inhibitory effect could be adsorbed using a full-length DT mutant or B-subfragment.  
A C-terminal truncation mutant could not adsorb the inhibitory effect, suggesting that  
15 the last 150 amino acids contain the epitope(s) recognized by the inhibitory antibodies.

Therefore, an anti-CD3 single-chain immunotoxin, sFv-DT390, was made with a  
truncated DT. The  $IC_{50}$  of sFv-DT390 was  $4.8 \times 10^{-11}$  M, 1/16 the potency of the  
divalent UCHT1-CRM9. More importantly, as shown in Table 2, sFv-DT390 toxicity  
20 was only slightly affected by the anti-DT antibodies in human sera. "sFv" and  
"scUCHT1" both are single chain antibodies containing the variable region.

Table 2: Anti-DT antibodies present in human sera have reduced effect on sFv-DT390 toxicity.

Serum Sample	ELISA value ( $\pm$ S.D.)	Protein synthesis (% Control)					
		UCHT1CRM9			sFv-DT390		
		1:10	1:10 <sup>2</sup>	1:10 <sup>3</sup>	1:10	1:10 <sup>2</sup>	1:10 <sup>3</sup>
10012	0.491 $\pm$ 0.025	119 $\pm$ 24	8 $\pm$ 2	ND*	47 $\pm$ 9	21 $\pm$ 8	ND
Pooled	0.331 $\pm$ 0.015	108 $\pm$ 37	7 $\pm$ 1	ND*	49 $\pm$ 7	16 $\pm$ 7	ND
Goat	1.450 $\pm$ 0.013	ND	ND	94 $\pm$ 21	ND	ND	8 $\pm$ 11

\*Not done

UCHT1CRM9 or sFv-DT390 ( $2 \times 10^{-9}$ M) was incubated with the indicated dilutions of serum for 30 min. The mixture was then added to Jurkat cells as described. The final concentration of immunotoxin on cells was  $1 \times 10^{-10}$ M. Four replicates were performed for each sample. Data are presented as a mean value  $\pm$  S.D. in percentage of the control counts. UCHT1-CRM9 inhibited protein synthesis to 5% of controls while the sFv-DT390 inhibited protein synthesis to 18% of controls. The ELISA value was determined using a 1:100 dilution of serum. The results are representative of two independent experiments.



**EXAMPLE 7**

**Expression and Characterization of a Divalent Chimeric  
Anti-human CD3 Single Chain Antibody**

5

Murine anti-CD3 monoclonal antibodies (mAbs) are used in clinical practice for immunosuppression. However, there are two major drawbacks of this treatment: the associated cytokine release syndrome and human anti-mouse antibody response. To overcome these side effects, a chimeric anti-human CD3 single chain antibody,

10 scUCHT1 was generated. It is an IgM variant of the UCHT1 as described. scUCHT1 consists of the light and heavy variable chain binding domains of UCHT1 and a human IgM Fc region ( $\mu$ CH2 to  $\mu$ CH4). The method used was reported by Shu et al. (37) and is further described below. The following data show that the engineered chimeric anti-CD3 single chain antibody (scUCHT1) will be useful in clinical immunosuppressive

15 treatment.

**Oligonucleotide primers and DNA amplification.**

Primers used for the antibody engineering are listed in Table 3, and the primer sequences are based on published data (13). mRNA isolated from UCHT1 hybridoma

20 cells (provided by Dr. P. C. Beverley, Imperial Cancer Research Fund, London) was reverse transcribed into cDNA. The VL and VH regions of UCHT1 were amplified with polymerase chain reaction (PCR) from the cDNA using primer pairs P1, P2 and P3, P4 respectively. Primers P2 and P3 have a 25 bp complementary overlap and each encoded a part of a linker peptide (Gly4Ser)<sup>3</sup>. The single chain variable fragment

25 (VL-linker-VH) was created by recombinant amplification of VL and VH using primers P1 and P4. a mouse kappa chain signal sequence was added at the VL 5'-end by PCR, first with primers SP2 and P4, and then with primers SP1 and P4. The human IgM Fc region ( $\mu$ CH2 to  $\mu$ CH4) was amplified from the plasmid pBlue-huIgM (kindly provided by Dr. S. V. S. Kashmiri, National Cancer Institute, Bethesda. This gene fragment was

30 about 1.8 kb. The VL-linker-VH- $\mu$ CH2 region which is important for antigen recognition was confirmed by sequence analysis. Finally, the single chain variable

fragment and the human IgM Fc region were cloned into plasmid pBK/CMV (Stratagene, La Jolla, CA, USA). Using the generated pBK/scUCHT1 plasmid as template, an *in vitro* transcription-translation assay yielded a product of 75 kDa, the expected size.

TABLE 3. Sequences of oligonucleotide primers used for PCR amplification

Primers	Sequences	RE sites
P1(UCHT1 VL5)	5' GACATCCAGATGACCCAGACC (SEQ ID NO:1) 3'	
P2(UCHT1 VL3)	CCTCCGAGCCACCGCCTCCGCTGCCTCCGCCCTCTTTATCTCCAGCTT G(T)GTC(G)CC (SEQ ID NO:2)	
P3(UCHT1 VH5)	GCAGCGGAGGCGGTGGCTCGGAGGGGAGGCTCGGAGGTGCAGCTTC AGCAGTCT (SEQ ID NO:3)	
P4(UCHT1 VH3)	GCAAGCTTGAAAGACTGTGAGAGTGGTGCCTTG (SEQ ID NO:4)	Hind III
P5(HuIgM-CH2)	GTCTCTTCAAAGCTTATTGCC(T)GAGCTGCCTCCCAA (SEQ ID NO:5)	Hind III
P6(HuIgM-CH4)	GCATCTAGATCAGTAGCAGGTGCCAGCTGTGT (SEQ ID NO:6)	Xba I
SP1 (Signal 1)	CGGTCGACACCATGGAGACAGACACTCCTGTTATGGGTACTGCTGCT CTGGGTTCCA (SEQ ID NO:7)	Sal I
SP2 (Signal 2)	GTAAGTCTGCTCTGGGTTCCAGGTTCCTGAGGAGATCCAGATGACCC AG (SEQ ID NO:8)	

### Expression in COS-7 and SP2/0 cells.

The gene fragment encoding scUCHT1 was then cloned into an expression vector pLNCX (36). The scUCHT1 gene construct was introduced into COS-7 cells with a calcium-phosphate method (32), and introduced into SP2/0 myeloma cells by electroporation (33). Cells transfected were selected with 500  $\mu$ g/ml G418 (GIBCO/BRL, Gaithersburg, MD, USA) in DMEM medium. The drug resistant transfectants were screened for scUCHT1 secretion by an anti-human IgM ELISA technique. Transfectants secreting scUCHT1 were cloned by limiting dilution.

Two stable clones, COS-4C10 and SP2/0-7C8, which could produce about 0.5 mg/ml scUCHT1 in culture medium, were selected for further evaluation. The culture supernatant of COS-4C10 and SP2/0-7C8 cells was analyzed by immunoblotting using anti-human IgM antibody. Human IgM antibody was included as a control in the analysis. Under reducing conditions, scUCHT1 produced by COS-7 and SP2/0 cells had a similar electrophoretic mobility to that of the control human IgM heavy chain (75 kDa). Under non-reducing conditions, scUCHT1 from COS-7 cells appeared as a single band of approximately 150 kDa, which was thought to be a homodimer of the single chain antibody. SP2/0 cells mainly produced a protein of similar size with some higher molecular weight products.

In constructing scUCHT1, the domain orientation of sFv, VH-VL, which Shu et al. used to VL-VH orientation, was changed so that the heavy chain constant domains were linked to the VH domain. In mammalian cells, secretion of immunoglobulin molecules is mediated by light chain, and free light chain is readily secreted (38). However, free heavy chain is generally not secreted (39). In a bacterial expression system, the yield of secreted sFv with a VL-VH domain orientation was about 20-fold more than that obtained with a VH-VL domain orientation (40). It was reasoned that VL at the NH<sub>2</sub>-terminal position and VH linked to heavy chain constant region in scUCHT1 construct might enhance the secretion of this immunoglobulin-like molecule in mammalian cells. In fact scUCHT1 was efficiently produced by both COS-7 and SP2/0 cells. Hollow fiber culture should increase its production. Moreover, scUCHT1, the

IgM-like molecule, has a secretory tailpiece with a penultimate cysteine (Cys 575) which is involved in polymerization and also provides retention and degradation of IgM monomers (41-43). Replacing the Cys 575 with serine might also greatly improve the yield.

5

scUCHT1 secreted from COS-7 cells was shown to be a divalent form by immunoblotting, suggesting a disulfide bond linkage of two monovalent molecules. The disulfide bond is likely situated between the  $\mu$ CH2 and  $\gamma$ CH3 regions, where the Cys 337-Cys 337 disulfide bond is thought to exist. Cys 337 is believed to be sufficient for  
 10 assembly of IgM monomers, and was neither sufficient nor necessary for formation of polymers. However, Cys 575 was necessary for assembly of IgM polymers, and Cys 414 was not required for formation of IgM monomers or polymers (44). This divalent form of the single chain antibody should increase its binding affinity. While scUCHT1  
 15 produced from SP2/0 cells was mainly in the divalent form, a small fraction of the antibody had a higher molecular weight, nearly comparable to that of the human IgM pentamer, the natural form of secreted human IgM.

#### **Western blotting analysis of scUCHT1.**

scUCHT1 was precipitated from the culture supernatant using goat anti-human  
 20 IgM-Agarose (Sigma, St. Louis, MO, USA), and separated on 4-20% SDS-PAGE gradient gel under reducing and non-reducing conditions. The separated proteins were transferred to ProBlott™ membrane (Applied Biosystems, Foster City, CA, USA) by electroblotting at 50 volts for 1 hour. The membrane was blocked and incubated with alkaline phosphatase labeled goat anti-human IgM antibody (PIERCE, Rockford, IL,  
 25 USA) following the manufacturer's instruction. Color development was carried out with substrate NBT/BCIP (PIERCE).

#### **Purification of scUCHT1**

Culture supernatant was mixed with anti-human IgM-Agarose, and incubated at  
 30 4°C with shaking overnight, and then the mixture was transferred to a column. The column was washed with washing buffer (0.01 M Na-phosphate, pH 7.2, 0.5 M NaCl)

until the OD280 of flow-through was  $<0.01$ . scUCHT1 was eluted with elution buffer (0.1 M glycine, pH 2.4, and 0.15 M NaCl). The fractions were neutralized with 1 M Na-phosphate (pH 8.0) immediately, and then concentrated and dialyzed against PBS.

## 5 Competitive binding assay

The parental antibody UCHT1 was iodinated using Bolton-Hunter Reagent (NEN, Wilmington, DE, USA) as described previously (34). The  $^{125}\text{I}$ -labeled UCHT1 was used as tracer and diluted with DMEM medium to 0.3-0.6 nM. UCHT1 and the purified scUCHT1 from COS-7 and SP2/0 transfectant cells were used as competitors.

10 Human CD3 expressing Jurkat cells were suspended in DMEM medium ( $2 \times 10^7/\text{ml}$ ). 50  $\mu\text{l}$  of such cell suspension ( $1 \times 10^6$ ) was incubated with 50  $\mu\text{l}$  diluted tracer and 50 ml diluted competitors on ice for 2 hours. Afterwards, cells were pelleted, and counted in a gamma counter. Results were expressed as a percentage of the  $^{125}\text{I}$ -UCHT1 bound to cells in the absence of competitors.

15

scUCHT1 from both COS-7 and SP2/0 cells could specifically inhibit the binding of  $^{125}\text{I}$ -UCHT1 to Jurkat cells in a dose dependent way. As the concentration of the competitors (UCHT1, scUCHT1 from COS-7 and SP2/0 cells) increased from 1 to 100 nM, the tracer ( $^{125}\text{I}$  iodinated UCHT1) bound to Jurkat cells decreased from 80% to

20 nearly 0%. No significant difference was observed among the affinity curves of UCHT1 and scUCHT1 from COS-7 and SP2/0 cells. This indicates that the engineered antibody scUCHT1 has nearly the same affinity as UCHT1. Moreover, scUCHT1 contains human IgM constant region, and is expected be less immunogenic than UCHT1. The degree of its immunogenicity might vary due to the murine variable region of scUCHT1.

25 Humanized variable regions by CDR-grafting or human variable regions can be used to further reduce its immunogenicity (31).

## T-cell proliferation assay.

T-cell proliferation in response to UCHT1 and scUCHT1 was tested on human

30 PBMCs from a healthy donor. Human peripheral blood mononuclear cells (PBMCs) were isolated from blood of a healthy adult by density centrifuge over Ficoll-Hypaque

gradient (34). The PBMCs were resuspended in RPMI 1640 supplemented with 10% FCS and aliquoted to 96-well U-bottom plates at  $5 \times 10^4$  cells/well. Increasing amounts of anti-CD3 antibodies (UCHT1, scUCHT1) were added. After 72 hours of culture at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>, 1  $\mu$ Ci [<sup>3</sup>H]thymidine (NEN) was added to each well. Sixteen hours later, cells were harvested and [<sup>3</sup>H]thymidine incorporation was counted in a liquid scintillation counter.

The parental antibody UCHT1 started to induce proliferation at 0.1 ng/ml, and peaked at 100 ng/ml. a small drop in CPM was observed as the concentration increased to 1,000 ng/ml. However, [<sup>3</sup>H]thymidine incorporation in PBMCs incubated with scUCHT1 was only slightly increased in the range of 0.1 - 10 ng/ml, and when the concentration was higher than 10 ng/ml, the incorporated counts decreased and were close to 0 counts at 1,000 ng/ml.

#### 15 **Measurement of TNF- $\alpha$ and IFN- $\gamma$**

TNF- $\alpha$  and IFN- $\gamma$  productions of human PBMCs induced by UCHT1 and scUCHT1 were measured with ELISA.  $4 \times 10^5$  PBMCs were cultured with serial dilutions of anti-CD3 antibodies (UCHT1, scUCHT1) in 96-well flat-bottom plates in RPMI 1640 supplemented with 10% FCS. Supernatant was collected at 36 hours for TNF- $\alpha$  and 72 hours for IFN- $\gamma$  after the start of the culture (35). TNF- $\alpha$  and IFN- $\gamma$  were measured with ELISA kits (Endogen Inc. Cambridge, MA, USA) following the manufacturer's instruction.

The native antibody UCHT1 induced production of both TNF- $\alpha$  and IFN- $\gamma$  in a dose dependent way. Higher concentration of UCHT1 induced higher production of TNF- $\alpha$  and IFN- $\gamma$ . On the contrary, scUCHT1 did not induce secretion of TNF- $\alpha$  at any concentration, and inhibited IFN- $\gamma$  production when its concentration was higher than 0.1 ng/ml. At the time of supernatant harvesting, the PBMCs cultured with UCHT1 and scUCHT1 were also checked with trypan blue exclusion test. Cells were shown to be alive in both situations. In TNF- $\alpha$  and IFN- $\gamma$  ELISA assays, an unrelated human IgM was included and it did not affect the TNF-a and IFN-g production.

### Measurement of Possible Complement Binding by scUCHT1

Divalent scUCHT1 failed to bind detectable quantities of complement. This feature is an advantage in treating patients with a foreign protein in that it will minimize immune complex disease.

5

Anti-CD3 mAbs can induce T cell activation and proliferation both in *in vitro* and *in vivo* situations (45). Crossing-linking of anti-CD3 antibody between T cells and FcR expressing cells is an essential step in this process (46). T cell activation therefore reflects an efficient interaction of the mAb with a human FcR. Previous data of *in vitro* study indicated that T cell activation resulted in increased production of TNF- $\alpha$ , IFN- $\gamma$ , and IL-2 (24). Human IgG Fc receptors (Fc $\gamma$ R I, Fc $\gamma$ R II, Fc $\gamma$ R III) are distributed on human monocytes, T, B lymphocytes, and NK cells (47). Fc $\gamma$ R I and Fc $\gamma$ R II can recognize both mouse and human IgG. In accordance with the above observation, UCHT1 was potent in induction of T cell proliferation and TNF- $\alpha$  and IFN- $\gamma$  release.

Human IgM Fc receptor (Fc $\mu$ R) was reported to be present mainly on a small fraction of B lymphocytes, NK cells, and possibly a helper subset of T lymphocytes (47, 48). Pentamer form of IgM and an intact  $\gamma$ CH3 domain are required for optimal binding to Fc $\mu$ R. Monomeric or dimeric subunits of IgM are less efficient in binding to Fc $\mu$ R (49, 50). Cross-linking of IgM to Fc $\mu$ R on T cells inhibited the mitogen-induced T cell proliferation, and Fc $\mu$ R may function as a negative signal transducing molecule (51, 52).

15  
20

Therefore, it can specifically bind to human CD3 molecule and Fc $\mu$ R. It is conceivable that scUCHT1 can cross-link human B and T cells, and possibly T and T cells. In an *in vitro* assay, scUCHT1 from both COS-7 and SP2/0 cells had little effect in the T cell proliferation assay at low concentrations (below 10 ng/ml), and became inhibitory as the concentration increased. In accordance with these results, scUCHT1 did not induce TNF- $\alpha$  production and even inhibited the basal yield of IFN- $\gamma$ .

25

The present chimeric anti-CD3 single chain antibody scUCHT1 possesses high human CD3 binding specificity and affinity, and does not induce T cell proliferation and cytokine release. Moreover, it has a human IgM Fc fragment, which should decrease the

30



possibility of inducing human anti-mouse antibody response. Thus, scUCHT1 can be used for clinical immunosuppressive treatment.

### EXAMPLE 8

5

#### **Immunotoxin Plus Short Term Immunosuppressant Drugs Induces Tolerance in Monkeys in Models Simulating Human Cadaveric Donors**

##### **Immunotoxin**

10 Techniques for preparing anti-CD3-CRM9 (where the antibody is directed at the human T-cell receptor complex "CD3") have previously been described. See U.S. patent 5,167,956 and D. Neville *et al.*, 89 P.N.A.S. USA 2585-2589 (1992). a hybridoma secreting UCHT1 was kindly provided by Dr. Peter Beverly, Imperial Cancer Research Fund, and was grown in ascites fluid and purified over immobilized Protein a. This is an  
15 IgG1.

FN18, also an IgG1, is the rhesus analog of UCHT1 and shares with it the property of being a T-cell mitogen in the presence of mixed mononuclear cells. FN18 was produced in hollow fiber and purified over Protein a. The strain of *C. diphtheriae*  
20 used for production of CRM9, C7 ( $\beta$ h tox-201 tox-9 h ) was obtained from R. Holmes, Uniformed Services University of Health Sciences, Bethesda, MD. See also V. Hu *et al.*, 902 Biochimica et Biophysica Acta 24-30 (1987).

Antibody-CRM9 was recovered from the supernatant of 30 liter fermentation  
25 runs under careful control of iron concentration. See S.L. Welkos *et al.*, 37 J. Virol. 936-945 (1981). CRM9 was purified by membrane concentration, ammonium sulfate precipitation and chromatography over DEAE. See S. Carroll *et al.*, 165 Methods In Enzymology 68 (1988).

30 Large scale purification of immunotoxin was accomplished by HPLC size exclusion chromatography on MODcol (1266 Andes Blvd., St. Louis, Missouri 63132)

2"x10" column packed with Zorbax (DuPont Company) GF-250 5 $\mu$ m, 150 Å. Fractions containing 1:1 toxin:antibody mol ratios were isolated for these studies.

Immunotoxins were synthesized as previously described by thiolating both the  
 5 monoclonal antibody moiety and the toxin moiety and then crosslinking with bismaleimido-hexane. See D. Neville et al., 264 J. Biol. Chem. 14653-14661 (1989). CRM9 was nicked and the monomer (Carroll et al.) was isolated by the MODcol column described above prior to thiolation.

10 While CRM9 is a presently preferred mutant diphtheria toxin protein, other preferred embodiments include diphtheria mutants with a mutation in the DT binding region, such as DT390 (as described), should also be suitable (as the concept behind the immunotoxin is to replace the normal binding function with the antibody provided T-cell binding function, with minimal conformational change).

15

#### **T-Cell Ablation**

Monoclonal antibody FN18 (specific for rhesus monkey T lymphocytes) coupled to the immunotoxin CRM9 was used to deplete peripheral blood T-cells to levels below 200 cells /ML3 in adult rhesus monkeys (measured six days after the injection). Some  
 20 modest B cell depletion occurred. Following depletion, complete T-cell recovery takes about three to four weeks in a juvenile rhesus monkey model using this agent. Surprisingly, notwithstanding this fast recovery, donor T-cells injected into the thymus still were not impaired in their ability to produce tolerance.

25 A group of rhesus monkeys undergoing mismatched renal transplantation received anti-CD3-CRM9 (IT) 18 hours pretransplant, 0.067 mg/kg and 0.033 mg/kg on days 0 and +1. Group 1 received only IT, n=6. Group 2, n=7, received in addition to IT deoxyspergualin (DSG) IV 2.5 mg/kg/day and solumedrol (SM), 7, 3.5 and 0.33 mg/kg IV during the IT administration. DSG was continued from 4 to up to 14 days. Plasma  
 30 samples were tested by ELISA for cytokine release syndrome by measuring pre and post transplant plasma IL-12 and INF gamma levels.

### Graft Survival (days)

	Group 1 (IT alone)	Group 2 (IT + DSG + SM)
5	10-57 n=6 (rejections)	>155-200 n=4
		28-45 n=3 (rejections)
		2 deaths from non-rejection causes

IT, Group I, (or rhesus anti-CD3 an antibody alone) elevated both IL-12 and  
 10 INF-8 gamma. DSG and solumedrol appear to block IL-12 induced activation of  
 INF-gamma by a mechanism that may be associated with NF-kappa/beta (Fig. 1). This  
 treatment is found to eliminate peritransplant weight gain and serum hypoproteinemia,  
 both signs of vascular leak syndrome, which in this study is associated with early graft  
 rejection. This peritransplant treatment regimen can provide a rejection-free window  
 15 for tolerance induction applicable to cadaveric transplantation.

It takes over 24 hours for IT to exert most of its lymph node T cell killing  
 effects. Therefore, IT cadaveric transplantation protocols (protocols in which organ  
 transplantation occurs generally within 6 hours of initial therapy and not longer than 18  
 20 hours) benefit substantially from peritransplant supplemental short term  
 immunosuppressant agents to minimize peritransplant T cell responses to the new  
 organ as shown by the above data.

### EXAMPLE 9

25 Reversal of diabetes in a non-insulin secreting monkey.

Monkey 0038 is a non-obese 7 kg African Green monkey of 20 years of age  
 who developed acute diabetic ketotic coma with a blood sugar of 950 mgm%. After  
 resuscitation this monkey was found to require exogenous insulin to prevent life  
 30 threatening hyperglycemia (4 units twice daily of a mixture of 70% NPH and regular  
 human insulins). However, on this therapy blood sugars were elevated, between

200-480 mgm% and glycosylated hemoglobin was greater than 10%. Serum insulins were undetectable on 12 occasions when exogenous insulin injections were withheld for 48-72 hours. C-peptide levels were less than 0.4 ng/ml (0.9 ng/ml normal). The beta cell failure documented in this monkey is presumably a result of long term peripheral insulin resistance.

The islet donor for monkey 0038 was a normal juvenile rhesus monkey of between 2-3 years of age. Pancreas procurement was by standard technique for human multiple organ procurement. The preservation solution was that used by the University of Wisconsin at 4°C. Cold ischemia time was 6-8 hours. Islet isolation was the semi-automated technique described by Dr. C. Ricordi, using Liberase (8). Islet yield was 80,000 I.E., viability > 90%. The islets were cultured overnight in RPMI1640 at 37°C with 10% normal monkey serum and 50,000 islets were transplanted the next day which is day 0. The transplant procedure was performed under anesthesia by a small midline abdominal incision, exposure and cannulation of the inferior mesenteric vein with a 5F feeding tube, and islet infusion by gravity into the portal vein via the inferior mesenteric vein.

#### Immune Tolerance Inducing Regimen

day -1 and day +1: 0.1 mg/kg anti-rhesus anti-CD3-CRM9 (FN18-CRM9 chemical conjugate) (6,9).IV infusion over 3 minutes in 0.1 M Na2SO4 + 0.01M NaP04, pH7.4 buffer.

day -1,0,1,2. Solumedrol (TM) 15 mg/kg/IV infused in ½ normal saline over 2.5 minutes starting 2 hrs prior to CD3-CRM9 on days -1 and 1.

day -1. Cyclosporine A, 20 mg/kg IV infused in ½ normal saline over 2.7 minutes.

day -1,0,1,2. Oral cyclosporine (Neoral, TM) 120 mg/kg/day in 2 equally divided doses.

Immunotoxin induced blood T cell depletion judged by %FN18+ cells

CD3-IT      71%

day 8	0%
day 28	48%
day 40	70%

(Pre-transplant anti-CRM9 titer in serum diluted 1:100 was positive at an  
 5 ELISA O.D. of 0.146 or 2.2 times blank value. In spite of these antibodies directed at  
 CD3-IT, significant T cell depletion was achieved)

#### Post Transplant Course

Caloric intake increased following transplant as did general activity.  
 10 Non-fasting blood glucose values began to fall by day 4, and the monkey was off  
 exogenous insulin by day 11. From day 12 and out to day 150 (the current duration of  
 follow up) the monkey is normoglycemic with a mean blood glucose of 90 mgm% (Fig  
 2a). Glycosylated Hemoglobin has fallen into the normal range (Fig. 2b). And  
 C-peptide levels, indicative of islet cell insulin secretion, have risen from a subnormal  
 15 level into a normal range (Fig 3a). a post transplant glucose tolerance test is near  
 normal and may  
 be normal for an elderly primate (Fig. 3b).

Monkey X550 is a long-term diabetic cynomolgous monkey who received 6  
 20 units of a mixture of human NPH and regular insulins twice daily, yet was severely  
 hyperglycemic with blood sugars above 300 mgm% and showed elevated glycosylated  
 hemoglobin values. This monkey was in the low normal range of C-peptide values  
 prior to transplant (Fig. 4a) indicating insulin secretion but likely at the low end of the  
 normal range. However, severe peripheral insulin resistance appears to be present  
 25 based on the high blood sugars obtained prior to islet cell transplant in the face of both  
 endogenous and exogenous insulin (see Fig. 4b).

Monkey X550 received an islet cell transplant from a rhesus donor using the  
 method described above and the same immune tolerance inducing regimen. Blood  
 30 glucose declined into the normal range post transplant (Fig. 4b). Exogenous insulin  
 was discontinued on day 5, and non-fasting blood glucose values have remained below

170 mgm% from day 12 to day 18 which is currently the last day of follow up. Post transplant C-peptide values have climbed from the low normal range into the mid normal range. The severe insulin resistance noted pre transplant seems to have been largely moderated by the presence of new islets. This would imply that in this case of

5 insulin resistant diabetes, (1) the original islets were playing a role in the insulin resistant state and (2) the insulin resistant state could be attenuated by new healthy islets even in the presence of the faulty islets.

It should be emphasized that these stable transplants cross species lines and are,

10 therefore, classified as congenic or xenogeneic transplants. Thus, this immune tolerance inducing regime should also be useful in more disparate islet cell transplantation combinations crossing families and orders such as pig or fish into human.

15 It should be emphasized that the anti-CD3 $\epsilon$  immunotoxin used here can be modified and constructed by genetic engineering provided that the essential features are maintained. These are:

1. The antibody moiety must be directed at CD3 $\epsilon$  and the antibody moiety must be divalent and maintain an affinity of greater than  $10^8 \text{ M}^{-1}$ .
- 20 2. The protein toxin moiety must be efficiently translocated by the CD3 $\epsilon$  receptor or the CD3 $\epsilon$  routing pathway.

Added benefits will accrue if the antibody moiety lacks binding to the macrophage a B cell high and low affinity receptors which permit morbidity through cytokine release syndrome.

25 Throughout this application various publications are referenced by numbers within parentheses. Full citations for these publications are provided below. Also, some publications mentioned hereinabove are hereby incorporated in their entirety by reference. The disclosures of these publications in their entireties are hereby

30 incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.

5

## REFERENCES

1. Nicholls, P. J., Johnson, V. G., Andrew, S. M., Hoogenboom, H. R., Raus, J. C. and Youle, R. J. (1993) *J Biol Chem* 268, 5302-5308.
2. Neville, D. J. (1987) *Ann N Y Acad Sci* 507, 155-1643.
3. Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T. B. and Murphy, J. R. (1987) *Protein Eng* 1, 493-498
4. Johnson, V. G. and Youle, R. J. (1989) *J Biol Chem* 264, 17739-17744
5. Kreitman, R. J., Chaudhary, V. K., Waldmann, T. a., Hanchard, B., Cranston, B., FitzGerald, D. J. and Pastan, I. (1993) *Leukemia* 7, 553-562
6. Murphy, J. R. (1988) *Cancer Treat Res* 37, 123-124
7. Laske, D. W., Ilercil, O., Akbasak, a., Youle, R. J. and Oldfield, E. H. (1994) *J Neurosurg* 80, 520-526
8. Neville, D. J., Scharff, J. and Srinivasachar, K. (1992) *J of Controlled Release* 24, 133-141
9. Neville, D. J., Scharff, J. and Srinivasachar, K. (1992) *Proc Natl Acad Sci U S a* 89, 2585-2589
10. Giannini, G., Rappuoli, R. and Ratti, G. (1984) *Nucleic Acids Res* 12, 4063-4069
11. Chang, T. M. and Neville, D. M. J. (1977) *J Biol Chem* 252, 1505-1514
12. Neville, D. J., Srinivasachar, K., Stone, R. and Scharff, J. (1989) *J Biol Chem* 264, 14653-14661
13. Shalaby, M. R., Shepard, H. M., Presta, L., Rodrigues, M. L., Beberley, P. C. L., Feldman, M. and Carter, P. (1992) *J Exp Med* 175, 217-225
14. Johnson, S. and Bird, R. E. (1991) in *Methods in Enzymol*, pp.88-98, Academic Press, Inc., San Diego, California

15. Grimont, F. and Grimont, P. A. D. (1991) in *Nucleic acid techniques in bacterial systematics*, pp. 252, E. A. G. Stackebrandt M. John Wiley and Sons, LTD, West Sussex, England
16. Esworthy, R. S. and Neville, D. M. J. (1984) *J Biol Chem* 258, 11496-11504
17. Pelchen-Matthews, A., Armes, J. E., Griffiths, G. and Marsh, M. (1991) *J Exp Med* 173, 575-578
18. Choe, S., Bennett, M. J., Fujii, G., Curmi, P. M., Kantardjieff, K. A., Collier, R. J. and Eisenberg, D. (1992) *Nature* 357, 216-222
19. LeMaistre, C. F., Meneghetti, C., Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Deisseroth, A., Woodworth, T. and Parkinson, D. R. (1992) *Blood* 79, 2547-2554
20. Plataniias, L. C., Ratain, M. J., O'Brien, S., Larson, R. A., Vardiman, J. W., Shaw, J. P., Williams, S. F., Baron, J. M., Parker, K. and Woodworth, T. G. (1994) *Leuk Lymphoma* 14, 257-262
21. Higashi, K., Asada, H., Kurata, T., Ishikawa, K., Hayami, M., Spriatna, Y., Sutarman, Y. and Yamanishi, K. (1989) *J Gen Virol* 70, 3171-3176
22. Youle, R. J. and Neville, D. M. J. (1982) *J Biol Chem* 257, 1598-1601
23. Williams, D. P., Snider, C. E., Strom, T. B. and Murphy, J. R. (1990) *J Biol Chem* 265, 11885-11889
24. Parlevliet et al. (1992) *Transplant Int*; 5:234-246.
25. Cosimi et al. (1981) *Transplantation*; 32:535-9.
26. Jaffers et al. (1986) *Transplantation*; 41:572-8.
27. Abramowicz et al. (1989) *Transplantation*; 47:606-8.
28. Burns et al. (1982) *J Immunol*; 129:1451-7.
29. Parren et al. (1991) *Res Immunol*; 142:749-63.
30. Waid et al. (1991) *Transplant Proc*; 23:1062-5.
31. Khazaeli et al. (1994) *J Immunotherapy*; 15:42-52.
32. Chen C and Okayama H. (1987); *Mol Cell Biol* 7:2745-52.
33. Slavin-Chiorini et al. (1993) *Int J Cancer* ; 53:97-103.
34. Rigaut KD, Scharff JE, Neville DM Jr. (1995) *Eur J Immunol*; 25:2077-82.



35. Woodle ES, Thistlethwaite JR, Jolliffe LK, et al. (1992) *J Immunol*;148:2756-63.
36. Miller AD, Rosman GJ. (1989) *BioTechniques* 7:980-90.
37. Shu LM, Qi CF, Schlom J, Kashmiri SVS (1993) *Proc Natl Acad Sci USA*;90:7995-9.
38. Mosmann TR, Williamson AR (1980) *Cell*; 20:283-92.
39. Capon DJ, Chamow SM, Mordenti J, et al. (1989) *Nature* 337:525-31.
40. Anand NN, Mandal S, MacKenzie CR, et al. (1991) *J Bio Chem* 266:21874-9.
41. Sitia R, Neuberger M, Alberini CM, et al. (1990) *Cell*;60:781-90.
42. Alberini CM, Bet P, Milstein C, Sitia R. (1990) *Nature* 347:485-7.
43. Fra AM, Fragioli C, Finazzi D, Sitia R, Alberini CM (1993) *The EMBO Journal*; 12:4755-61.
44. Wiersma EJ, Shulman MJ (1995); 154:5265-72.
45. Smith KG, Austyn JM, Hariri G, Beverley PC, Morris PJ (1986) *Eur J Immunol*; 16:478-86.
46. Tax WJ, Hermes FF, Willems RW, Capel PJ, Koene RA (1984) *J Immunol*;133:1185-9.
47. Lynch, RG, Sandor M., Metzger H, ed. Washington DC: American Society for Microbiology 1990:305-34.
48. Moretta I, Webb SR, Grossi CE, Lydyard M, Cooper MD. (1977) *J Exp Med*;146:184-200.
49. Ferrarini M, Moretta L, Mingari MC, Tonda P, Pernis B. (1976) *Eur J Immunol*;6:520-1.
50. Mathur a, Lynch RG, Kohler G (1988);*J Immunol*; 140:143-7.
51. Pricop L, Rabinowich H, Morel PA, Sulica a, Whiteside TL, Herberman RB (1993) *J Immunol*; 151:3018-29.
52. Emara M, Sanfilippo F (1992) *Cell Immunol*; 144:143-54.
53. Glu M, Gordon VM, Fitzgerald DJ, Leppla S (1996) *Infect. and Immun.*; 64(2):524-527.
54. Kuan CT, Pastan I (1996) *Proc. Natl. Acad. Sci. USA*; 93:974-978, 1996.

55. Francisco JA, Kiener PA, Moran-Davis P, Ledbetter JA, Siegall CB (1996) *J. Immunol.*; 157:1652-1658.
56. Kaczorek M, Delpeyroux F, Chenciner N, Streeck R (1983) *Science*; 221:855
57. Shen WH, Choe S, Eisenberg D, Collier RJ (1994) . *Biol. Chem.*; 469(46):29077-29084.
58. Muhlrad D, Hunter R, Parker R (1992) *Yeast*; 8:79-82.
59. Madshus IH, Stenmark H, Snadvig K, Olsnes S (1991) *J. Biol. Chem.*; 266(26):17446-53.
60. Federal Register, Notices, May 7, 1986), Appendix F-II-B, p. 16971.
61. Perkins SJ, Nealis AS, Sutton BJ, Feinstein a (1991) *J. Mol. Biol.*, 221:1345-1366.
62. Theuer, CP, Kreitman RJ, FitzGerald DJ, Pastan I (1993) *Cancer Res.*, 53:340-347.
63. Kihara a, Pastan I (1994) *Cancer Res.*, 54:5154-5159.
64. Chaudry GJ, Fulton RJ, Draper RK (1993) *J. Biol. Chem.*, 268(13):9437-9441.
65. Schmidt M, Hynes NE, Groner B, Wels W (1996) *Int. J. Cancer*, 65:538-546.
66. Better M, Bernhard SL, Lei SP, Fishwild DM, Lane JA, Carroll SF, Horwitz AH (1993) *Proc. Natl. Acad. Sci USA*, 90:457-461.
67. Thompson J, Hu H, Scharff J, Neville, Jr. D (1995) *J. Biol. Chem.*, 24:28037-28041.
68. Ma S, Thompson J, Hu H, Neville, Jr. D (1996) *Scand. J. Immunol.* 43:134-139.
69. Neville, Jr. D, Scharff J, Hu H, Rigaut K, Shiloach J, Singerland W, Jonker M (1996) *J. Immunotherapy* 19(2):85-92.
70. Knechtle S, Vargo D, Fechner J, Zhai Y, Wang J, Hanaway M, Scharff J, Hu H, Knapp L, Watkins D, Neville, Jr. D (1997) *Transplantation* 63(6):1-6.
71. Cellular and Molecular Approaches to Achieving Euglycemia (1997), NIH Guide 26(38).
72. Krowlewski AS, Laffel LMB, Krolewski M, Quinn M, Warram JH (1995) *N. Engl. J. Med.* 332:1251-55.

73. Alejandro R, Lehmann R, Ricordi C, Kenyon S, Angelico MC, Burke G, Esquenazi V, Nery J, Betancourt AE, Kong SS, Miller J, Mintz DH (1997) *Diabetes* 46:1983-89.
74. Henretta J, McFadden T., Pittman K, Thomas J, Thomsa F (1994) *Transplantation Proceedings* 26: 1138-39.
75. Rilo HLR, Carroll PB, Shapiro R, Jordan M, Scantlebury V, Rastellini C, Fontas P, Alejandro R, Mintz DH, Fung JJ, Ricordi C, Starzl TE, Rao AS (1995) *Transplantation Proceedings* 27:3162-63.

(I) APPLICANT: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services; and UAB Research Foundation

(iii) NUMBER OF SEQUENCES: 14

(A) ADDRESSEE: NEEDLE & ROSENBERG, P.C.  
(B) STREET: 127 Peachtree Street, N.E., Suite 1200  
(C) CITY: Atlanta  
(D) STATE: GA  
(E) COUNTRY: USA  
(F) ZIP: 30303-1811

(a) MEDIUM TYPE: Diskette  
(B) COMPUTER: IBM Compatible  
(C) OPERATING SYSTEM: DOS  
(D) SOFTWARE: FastSEQ for Windows Version 2.0

(a) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

(a) APPLICATION NUMBER:  
(B) FILING DATE:

(A) NAME: Spratt, Gwendolyn D.  
(B) REGISTRATION NUMBER: 36,016  
(C) REFERENCE/DOCKET NUMBER: 14014.0284

(a) TELEPHONE: 404 688 0770  
(B) TELEFAX: 404 688 9880  
(C) TELEX:

(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

GACATCCAGA TGACCCAGAC C

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 58 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCTCCCGAGC CACCGCCTCC GCTGCCTCCG CCTCCTTTTA TCTCCAGCTT GTGTCGCC 58

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 56 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCAGCGGAGG CGGTGGCTCG GGAGGGGGAG GCTCGGAGGT GCAGCTTCAG CAGTCT 56

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCAAGCTTGA AGACTGTGAG AGTGGTGCCT TG 32

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GTCTCTTCAA AGCTTATTGC CTGAGCTGCC TCCCAA 37

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GCATCTAGAT CAGTAGCAGG TGCCAGCTGT GT

32

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 59 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CGGTCGACAC CATGGAGACA GACACACTCC TGTATGGGT ACTGCTGCTC TGGGTTCCA

59

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GTACTGCTGC TCTGGGTTCC AGGTTCCA CT GGGGACATCC AGATGACCCA G

51

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 67 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGAAATACC TATTGCCTAC GGCAGCCGCT GGATTGTTAT TACTGCGCTG CCAACCAGC  
GATGGCC

60

67

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 54 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ATGAAATACC TATTGCCTAC GGCAGCCGCT GGATTGTTAT TACTGCTGC CCAA

54

## (2) INFORMATION FOR SEQ ID NO:11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 59 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGATTGTTAT TACTCGCTGC CCAACAAGCG ATGGCCGGCG CTGATGATGT TGTGATTC

59

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CGGTACTATA AAACCTCTTTC CAATCATCGT C

31

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GACGATGATT GGAAAGAGTT TTATAGTACC G

31

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGATCTGTCG A/CTCATCAGC TTTTGATTTC AAAAAATAGC G

41